Literature DB >> 5316907

Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

R Gold, M S Artenstein.   

Abstract

A second large-scale field trial of group C meningococcal polysaccharide vaccine in US Army recruits confirmed the efficacy and safety of the vaccine. When the results of all studies over a 2-year period were combined, the reduction in group-specific disease rates was 89.5%.

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5316907      PMCID： PMC2427931     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


  10 in total

1.  Serological typing of meningococci by means of micro-precipitation.

Authors:  K W SLATERUS
Journal:  Antonie Van Leeuwenhoek       Date:  1961       Impact factor: 2.271

2.  Respiratory disease and the adenoviruses.

Authors:  E L Buescher
Journal:  Med Clin North Am       Date:  1967-05       Impact factor: 5.456

3.  Prevalence of meningococcal serogroups and description of three new groups.

Authors:  J R Evans; M S Artenstein; D H Hunter
Journal:  Am J Epidemiol       Date:  1968-05       Impact factor: 4.897

4.  Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964-70.

Authors:  M S Artenstein; H Schneider; M D Tingley
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

5.  Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; W C Branche; C Harkins
Journal:  J Infect Dis       Date:  1970-04       Impact factor: 5.226

6.  Evaluation of group C meningococcal polysaccharide vaccine in marine recruits, San Diego, California.

Authors:  L F Devine; W E Pierce; T M Floyd; S L Rhode; E A Edwards; E E Siess; R O Peckinpaugh
Journal:  Am J Epidemiol       Date:  1970-07       Impact factor: 4.897

7.  Prevention of meningococcal disease by group C polysaccharide vaccine.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; H Schneider; C Harkins
Journal:  N Engl J Med       Date:  1970-02-19       Impact factor: 91.245

8.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307
  10 in total
  40 in total

Review 1.  Vaccine trials.

Authors:  C P Farrington; E Miller
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

2.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada.

Authors:  P De Wals; M Dionne; M Douville-Fradet; N Boulianne; J Drapeau; G De Serres
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

5.  Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.

Authors:  L Salleras; A Domínguez; G Prats; I Parron; P Muñoz
Journal:  J Epidemiol Community Health       Date:  2001-04       Impact factor: 3.710

Review 6.  Diagnosis and management of bacterial meningitis.

Authors:  G Hambleton; P A Davies
Journal:  Drugs       Date:  1974       Impact factor: 9.546

7.  A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.

Authors:  M H Wahdan; S A Sallam; M N Hassan; A Abdel Gawad; A S Rakha; J E Sippel; R Hablas; W R Sanborn; N M Kassem; S M Riad; B Cvjetanović
Journal:  Bull World Health Organ       Date:  1977       Impact factor: 9.408

8.  Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.

Authors:  L Y Wang; C E Frasch
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

9.  Should university students be vaccinated against meningococcal disease in Canada?

Authors:  Philippe De Wals
Journal:  Can J Infect Dis       Date:  2004-01

10.  Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens.

Authors:  J Melancon; R A Murgita; I W Devoe
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.